Event-free survival of children and adolescents with ALK-positive anaplastic large cell lymphoma (ALCL) reaches 65-75% with current chemotherapy regimen. Risk stratification of children with ALCL was, until now, based on clinical parameters. More recently, pathological and biological risk factors have been described in trials applying BFM-type chemotherapy. Histological subtypes containing small-cell or lymphohistiocytic components indicate a high risk of failure. Minimal disseminated disease (MDD) detected by qualitative RT-PCR for NPM-ALK in bone marrow or blood is associated with a relapse risk of 50%. Quantification of MDD and persistent minimal residual disease (MRD) characterize very high risk patients. Serum ALK-autoantibody titres inversely correlate with relapse risk. The combination of MDD and ALK-antibody titre separates both low and very high risk patients from those with standard risk. In relapse, the time of relapse/progression, central nervous system and bone marrow involvement are major risk factors. In conclusion, MDD, MRD, ALK-antibody titres and histological subtype are strong biological risk factors in childhood ALCL. The combination of MDD and ALK-antibody titre may serve for patient stratification in upcoming clinical trials.
coworkers (1). ALCLs were separated from other large cell lymphomas by the large anaplastic cells with horseshoe-like nuclei, sinusoidal growth pattern and the expression of the surface marker Ki-1 (CD30). In the late 1980s several groups described an association of the specific translocation t(2;5)(p23;q35) with ALCL. Morris and coworkers reported the molecular basis of the translocation in 1994, the fusion of the genes for nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) (2). One next step in history of ALK-positive ALCL was the production of the ALK1 monoclonal antibody by Karen Pulford in 1997 which allowed for accurate diagnosis of the disease (3). Several groups unravelled the molecular pathogenesis of ALK-positive ALCL during the following 15 years by demonstrating that lymphoma pathogenesis and survival depends on activated ALK-kinase signaling and by describing its signaling pathways (Review: (4, 5). This allowed for the preclinical development of several new treatment targets. During the last years the detection of the immunogenicity of ALK fusion proteins led to the exploration of further possible therapeutic options (6-12). The short time of less than 25 years from the first pathological description of the disease to the understanding the molecular pathogenesis resulted in the incorporation of ALK-positive ALCL as distinct entity in the 2008 WHO-classification for hematologic malignancies (13).
In light of new treatment options stringent prognostic factors are urgently needed for therapy stratification. Biomarkers detecting high risk patients would allow selecting patients for early clinical trials with new targeted therapies or allogeneic blood stem cell transplantation (SCT), whereas low risk patients could be treated less intensively or by immunostimulation. The evolution of a standard therapy for children with ALCL in Europe during the 1990s and 2000s provided the opportunity to test several pathological and biological markers for their prognostic value. The current standard strategy consists of six courses short-pulse chemotherapy given over a time period of five months (15, 20) . Modifications of the chemotherapy courses have been modest over the last 25 years and were not accompanied by a change in relapse rate so that large cohorts of uniformly treated children and adolescents with ALCL are available for risk factor analyses.
PROGNOSTIC FACTORS FRONT-LINE

Clinical risk factors
Clinical characteristics were analysed for their prognostic value already in the first national trials on childhood ALCL. However, different factors turned out to be significantly associated with outcome in each trial, and low patient numbers did not allow drawing definitive conclusions (17, 20, 21, 24) . 70% of patients present with advanced stage disease. Unlike mature B-NHL, the stage did not impact on the relapse risk in ALCL. A negative prognostic impact of skin involvement was described in the first Berlin-Frankfurt-Muenster (BFM)-group series (24). The French Society of Paediatric Oncology (SFOP) and UK Children's Cancer and Study group (UKCCSG) -studies identified mediastinal and visceral involvement (liver, spleen, lung) as factors associated with a high risk of relapse (17, 21). None of these factors turned out to be of significant prognostic value in the BFM90 trial in which B-symptoms correlated with relapse risk (20). Analyses of cumulative data from European national studies from the 1990s identified mediastinal involvement, visceral involvement, and skin lesions as poor prognostic factors (25). 64% of the analysed 225 patients had at least one clinical risk factor. Progression-free survival (PFS) and overall survival (OS) were significantly lower for patients with at least one clinical risk factor (61% and 73%, respectively) compared to patients without (89% and 94%, respectively) (25). These factors have been used for patient stratification in the first randomised clinical trial of the European InterGroup for Childhood Non-Hodgkin lymphoma (eicnhl), ALCL99 (15, 26), leading to the expected patient distribution into standard and high risk groups(15). ALCL was complicated by haemophagocytosis in 12% of children and adolescents in a large single centre analysis without impacting on the outcome of the patients (27).
Radiological risk factors
Imaging is implicated in staging and definition of risk organ involvement in ALCL. Early treatment response has not been analysed for its prognostic value in clinical trials so far. The observation that even a residual mass at the end of treatment does not mean failure in ALCL suggests that early response should not be used for treatment modification before studying its impact on outcome. There are only few data on 18-Fluordesoxyglucose (FDG)-positron emission tomography (PET)-(CT) in ALCL. These limited reports support the view that systemic ALCL usually are "PETpositive" (28-30). However, there are currently no data indicating that the addition of PET improves staging above conventional imaging. Furthermore, the available data do not allow connecting early PET-response with outcome in ALK-positive ALCL (28, 31). The potential role of PET-response in ALK-positive ALCL needs to be addressed in upcoming clinical trials.
Pathological risk factors
Histological subtypes of ALCL were defined during the 1990s. The current WHO classification distinguishes the common type ALCL from the small cell and the lymphohistiocytic variant, as well as the mixed type with more than one subtype in a biopsy (13). It was noted already early that certain histological subtypes might indicate a higher risk of relapse (17). The lymphohistiocytic subtype correlated with lower eventfree survival (EFS) in univariate but not in multivariate analysis among 82 patients treated according to the subsequent trials HM89 and HM91 of the SFOP (17). In an analysis of 80 paediatric NPM-ALK-positive ALCL of the BFM group all "not common" histological subtypes (i.e., small cell, lymphohistiocytic, and mixed) were associated with a higher risk of relapse. In a Cox regression analysis with the co-variables minimal disseminated disease (MDD), histologic subtype and clinical risk features, MDD in bone marrow (BM) and "not common" histology remained independent prognostic factors with similar risk ratios (32) . The strong prognostic impact of morphologic and phenotypic characteristics was confirmed among 375 patients with systemic ALK positive ALCL included in the ALCL 99 study of the eicnhl (16 (33) . CD56-positivity was observed rarely (7%) and was associated with poorer EFS in univariate analysis. This finding was not observed in a Children´s Oncology Group (COG) report but consistent with an earlier single centre analysis including ALK-positive as well as ALK-negative ALCL (34, 35) . CD8 expression correlated with non-common histological subtype and clinical high risk features, and was associated with a significantly poorer outcome in univariate and multivariate analyses including the co-variables CD8-expression, histological subtype and clinical risk features (CD8-positive versus CD8-negative: EFS 29% versus 68%, OS 57% versus 84%, respectively) (33).
A few additional immune histology based prognostic factors were described in smaller case series usually including adults and children, ALK-positive as well as ALK-negative ALCL. A single centre analysis correlated survivin expression with outcome (36) . More than 5% active caspase 3 expressing cells was associated with improved survival in an analysis of ALKpositive and -negative ALCL (37).
Bone marrow involvement / disseminated disease, involvement of central nervous system
Microscopic BM involvement is an uncommon event in ALCL. The frequency depends on the method used. It ranges from 5-10% by aspiration cytology to 10-15% by BM histology and more than 20% by immunohistochemistry with CD30 and EMAstaining (15, 17, 20-23, 38). Correspondingly, leukemic ALCL is exceedingly rare accounting for less than 3% of ALCL (39, 40) . Microscopic BM infiltration detected by aspiration cytology was associated with a poor prognosis in one BFM-group analysis including patients from two consecutive trials but not in earlier national trials with lower patient numbers (17, 20-23,32). BM infiltration detected by immunohistology, also correlated with the risk of relapse (38) . The fusion gene transcript NPM-ALK can be detected by a sensitive RT-PCR in about 50-60% of patients and implicates a significantly higher relapse risk compared to BM-PCR-negative patients (see below) (32, 41) . Comparison of results of quantitative PCR for NPM-ALK in BM and correspondent aspiration cytology suggests that ALCL-cells might easily be missed by microscopy (32) . Furthermore, comparison of both qualitative and quantitative PCR for NPM-ALK between BM and blood (PB) showed high concordance (32, 42) . Slightly more patients were positive in PB, and positive patients tended to have higher NPM-ALK copy numbers in PB compared to BM suggesting that detection of disseminated ALCL cells is rather a sign of circulating tumour cells than true BM infiltration.
Only 1-3% of children with ALCL present with central nervous system (CNS)-disease. The low number of patients precludes a detailed analysis of a possible prognostic value. Altogether, children with CNS-involvement have a survival chance of 50-60% with intensive B-NHL-type CNS-directed therapy with or without cranial irradiation (43,44).
ALK-related biological risk factors
All ALCL-cells express ALK-fusion genes in ALKpositive ALCL. They are dependent on ALK-signaling. In addition, ALK normal tissue distribution is restricted to few neurons in the CNS. This allowed exploring ALK as minimal disease marker as well as the patients´ immune response against ALK as potential risk factor.
MDD represents a small numbers of tumour cells present in BM or PB of a patient at diagnosis, whereas minimal residual disease (MRD) defines tumour cells remaining detectable during treatment. Generally, MDD and MRD are measured by polymerase chain reaction, a highly sensitive technique, or flow cytometry. In ALCL, a Reverse Transcriptase (RT)-PCR for NPM-ALK mRNA allows detecting 1 tumour cell among 10 5 to 10 6 normal cells (32, 41 with clinical risk factors and non-common histology, thus confirming the earlier observations. The 5-year EFS was 51% for MDD-positive and 83% for MDD-negative patients, respectively (p<0.001).
The same RT-PCR method was used by the AIEOP-and BFM-groups to study the prognostic impact of early MRD measured before the second course of chemotherapy (47). The EFS of 52 MDD-positive patients was significantly higher for 26 MDD-positive/MRDpositive than for 26 MDD-positive/MRD-negative patients (19% versus 69%, p<0.01) (Figure 1) (47) . The strong impact of MRD in multivariate analysis may allow early identification of patients with chemoresistant disease.
ALK over-expression induces a host immune reaction, giving rise to circulating autologous anti-ALK antibodies in more than 90% of patients (6-8, 46, 48). First data suggested that anti-ALK antibody titres inversely correlated with lymphoma dissemination and risk of relapse (8, 48). The prognostic value of the strength of the anti-ALK antibody response was analysed in detail in a common AIEOP -BFM-study including 128 NPM-ALKpositive ALCL patients (46). The 5-year PFS was 42% for 39 patients with low antibody titre (≤1/750) compared to 79% for 89 patients with high antibody titer (>1/750) (p<0.001).
This large group of uniformly treated children and adolescents with NPM-ALK-positive ALCL and availability of clinical data, histopathology, MDD and ALKantibody titre allowed detailed analysis of the described risk factors (46) ( Table 1 ). The combination of the parameters MDD and ALK-antibody titre for the first time allowed identifying not only a high-risk group of patients but also a very low-risk group amenable to therapy reduction (46). The following 3 subgroups of patients with different prognosis could be identified: 1) a biological high risk group (bHR) defined by MDD-positivity and antibody titre ≤1/750 (20% of patients); 2) a biological low risk group (bLR) defined by MDD negativity and an antibody titre >1/750 (31% of patients); 3) a biological intermediate risk group (bIR) including all other patients (48%; MDD negative/antibody titre ≤1/750 or MDD positive/antibody titre >1/750). PFS was 25% for bHR patients and 92% for bLR patients (p<0.001) (Figure 2A ). The bIR group showed a 5-years PFS of 68% and was predominantly composed of patients with high antibody titre/MDD positivity (79%). The 5-years OS was 71% for bHR patients, 83% for bIR cases and 97% for bLR patients (p=0.02) ( Figure 2B ) In multivariate analysis including the co-variables stage (St Jude), peripheral lymph nodes, mediastinal involvement, visceral involvement, BM involvement, histological subtype, MDD, antibody titre and biological risk group, the biological high risk group (bHR) and a non-common histology remained independent prognostic factors (hazard ratio 4.98 and 2.7, respectively) (46). 
RISK FACTORS AT RELAPSE
Patients with relapsed ALCL have a 30-60% chance to reach a second continuous remission (58) (59) (60) . Cure can even be reached after several relapses. The analyses of prognostic factors in relapse are hampered by several factors: first, the available data are until now limited to three retrospective reports (58) (59) (60) . Secondly, therapies at relapse were as different as maintenance treatment with vinblastine, autologous and allogeneic SCT (21, 58-63). However, considering the efficacy of these highly variable therapies, identification of risk factors for second relapse and death would allow for treatment stratification upon relapse.
The time from initial diagnosis to relapse or progression turned out as major risk factor for children and adolescents with relapsed ALCL (58, 60) . 24 of 41 children with relapsed ALCL in the French series relapsed during the first 12 months after initial diagnosis. They had a significantly lower disease-free survival (DFS) of 28% compared patients with later relapses (DFS 68%, p=0.01) (58) . Patients with disease progression or early relapse had a tendency towards lower OS among 26 relapse patients reported from Japan (59) . Among 74 children with ALCL-relapse after comparable first-line therapy reported by the BFM-group, the prognostic impact of the time of relapse could be confirmed. The relapse strategy recommended re-induction chemotherapy followed by autologous SCT. Only four of the 16 patients (25%) with progression during frontline therapy survived compared to 38 of the 58 patients with relapses after first line therapy (66%; p=0.02) (60) . EFS and OS of the 40 patients relapsing after therapy but within 12 months from initial diagnosis were 50% and 57%, respectively, compared to 67% and 83% of the 18 patients with a relapse later than one year after initial diagnosis (p=0.14 for EFS and 0.06 for OS). About 15% of children and adolescents present with BM or CNS -involvement in relapse (58, 60) which correlated with reduced survival in one analysis (60) whereas the affection of new sites outside BM or CNS was without impact on outcome (59, 60).
Besides the major risk factor, time to failure, expression of the T-cell antigen CD3 was associated with a high risk of failure in patients consolidated by autologous SCT in the retrospective BFM-series. However, the possible prognostic value of CD3-positivity cannot readily be generalised currently due to low patient numbers and retrospective analysis with lack of a defined cut-off for CD3-positivity. Whether MDD or ALK-antibody titres at the time of relapse can identify patients at risk for further relapse or death is subject of an ongoing prospective analysis.
FUTURE DIRECTIONS
Brentuximab vedotin, crizotinib and other ALKinhibitors are emerging as new targeted treatment options for CD30-positive and ALK-positive malignancies (64) (65) (66) (67) with promising first clinical data on safety and response. However, long-term data on possible late effects especially in children are still missing. Weekly Vinblastine monotherapy has been shown to be effective in relapse almost without risk of late effects (61, 68) . Risk stratified clinical trials are necessary to define the role of these new drugs or principles in the therapeutic strategy against ALK-positive ALCL. High-risk patients could be eligible for early phase clinical trials. Lowrisk patients should not be objected to new drugs with unknown possible late effects but could be eligible to test a less toxic chemotherapy backbone. Currently, the combination of MDD and histological subtype or MDD and ALK-antibody titres allow separating a group of 30% very good risk and 20% very high risk patients from those with an intermediate risk. MDD and ALK-antibody titre can be determined within one to two weeks from a single EDTA blood sample before the start of therapy. These parameters have therefore been chosen to be used for risk stratification in the forthcoming ALCL-trial of the EICNHL.
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